| Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody D Dubey, SJ Pittock, KN Krecke, PP Morris, E Sechi, NL Zalewski, ... JAMA neurology 76 (3), 301-309, 2019 | 360 | 2019 |
| Neurological complications associated with anti–programmed death 1 (PD-1) antibodies JC Kao, B Liao, SN Markovic, CJ Klein, E Naddaf, NP Staff, T Liewluck, ... JAMA neurology 74 (10), 1216-1222, 2017 | 314 | 2017 |
| Skeletal muscle alterations in patients with acute Covid‐19 and post‐acute sequelae of Covid‐19 MN Soares, M Eggelbusch, E Naddaf, KHL Gerrits, M van der Schaaf, ... Journal of cachexia, sarcopenia and muscle 13 (1), 11-22, 2022 | 213 | 2022 |
| Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study V Bril, A Drużdż, J Grosskreutz, AA Habib, R Mantegazza, S Sacconi, ... The Lancet Neurology 22 (5), 383-394, 2023 | 142 | 2023 |
| Clinical spectrum of high-titre GAD65 antibodies A Budhram, E Sechi, EP Flanagan, D Dubey, A Zekeridou, SS Shah, ... Journal of Neurology, Neurosurgery & Psychiatry 92 (6), 645-654, 2021 | 119 | 2021 |
| Inclusion body myositis: update on pathogenesis and treatment E Naddaf, RJ Barohn, MM Dimachkie Neurotherapeutics 15 (4), 995-1005, 2018 | 88 | 2018 |
| Chronic inflammatory demyelinating polyradiculoneuropathy—diagnostic pitfalls and treatment approach AM Stino, E Naddaf, PJ Dyck, PJB Dyck Muscle & nerve 63 (2), 157-169, 2021 | 59 | 2021 |
| Epidemiology and natural history of inclusion body myositis: a 40-year population-based study S Shelly, MM Mielke, J Mandrekar, M Milone, FC Ernste, E Naddaf, ... Neurology 96 (21), e2653-e2661, 2021 | 58 | 2021 |
| Sporadic late-onset nemaline myopathy: clinical spectrum, survival, and treatment outcomes E Naddaf, M Milone, A Kansagra, F Buadi, T Kourelis Neurology 93 (3), e298-e305, 2019 | 49 | 2019 |
| Survival and associated comorbidities in inclusion body myositis E Naddaf, S Shelly, J Mandrekar, AM Chamberlain, EM Hoffman, ... Rheumatology 61 (5), 2016-2024, 2022 | 47 | 2022 |
| Inclusion body myositis: update on the diagnostic and therapeutic landscape E Naddaf Frontiers in Neurology 13, 1020113, 2022 | 45 | 2022 |
| Clinical spectrum of Castleman disease–associated neuropathy E Naddaf, A Dispenzieri, J Mandrekar, ML Mauermann Neurology 87 (23), 2457-2462, 2016 | 42 | 2016 |
| Thrombocytosis distinguishes POEMS syndrome from chronic inflammatory demyelinating polyneuropathy E Naddaf, A Dispenzieri, J Mandrekar, ML Mauermann Muscle & Nerve 52 (4), 658-659, 2015 | 41 | 2015 |
| Myopathy With SQSTM1 and TIA1 Variants: Clinical and Pathological Features Z Niu, CS Pontifex, S Berini, LE Hamilton, E Naddaf, E Wieben, RA Aleff, ... Frontiers in neurology 9, 147, 2018 | 33 | 2018 |
| Guillain-Barre syndrome in a patient with evidence of recent SARS-CoV-2 infection E Naddaf, RS Laughlin, CJ Klein, M Toledano, ES Theel, MJ Binnicker, ... Mayo Clinic Proceedings 95 (8), 1799, 2020 | 32 | 2020 |
| Hereditary myopathies with early respiratory insufficiency in adults E Naddaf, M Milone Muscle & nerve 56 (5), 881-886, 2017 | 32 | 2017 |
| Vasculitic neuropathies E Naddaf, PJB Dyck Current treatment options in neurology 17, 1-15, 2015 | 29 | 2015 |
| 272nd ENMC international workshop: 10 Years of progress-revision of the ENMC 2013 diagnostic criteria for inclusion body myositis and clinical trial readiness. 16-18 June 2023 … JB Lilleker, E Naddaf, CGJ Saris, J Schmidt, M de Visser, CC Weihl Neuromuscular Disorders, 2024 | 27 | 2024 |
| Chloroquine and hydroxychloroquine myopathy: clinical spectrum and treatment outcomes E Naddaf, P Paul, OF AbouEzzeddine Frontiers in neurology 11, 616075, 2021 | 24 | 2021 |
| Atypical presentations of inclusion body myositis: Clinical characteristics and long‐term outcomes M Alamr, MV Pinto, E Naddaf Muscle & Nerve 66 (6), 686-693, 2022 | 23 | 2022 |
Teerin LiewluckMayo ClinicVerificeret mail på mayo.edu